• 1. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 2. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 3. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555

Professional Introduction to Compound with CAS No. 144042-81-9 and Product Name: 7-Methyl-5,6,7,8-tetrahydroimidazo1,2-apyridine

The compound with the CAS number 144042-81-9 and the product name 7-Methyl-5,6,7,8-tetrahydroimidazo1,2-apyridine represents a significant advancement in the field of chemical biology and pharmaceutical research. This heterocyclic compound has garnered considerable attention due to its unique structural properties and potential therapeutic applications. The molecular framework of 7-Methyl-5,6,7,8-tetrahydroimidazo1,2-apyridine consists of a fused imidazole and pyridine ring system, which is a motif frequently encountered in biologically active molecules. Such structural features often contribute to favorable interactions with biological targets, making this compound a promising candidate for further investigation.

Recent studies have highlighted the importance of tetrahydroimidazo[1,2-a]pyridine derivatives in drug discovery. These compounds exhibit a range of pharmacological activities, including anti-inflammatory, antimicrobial, and anticancer properties. The presence of the methyl group at the 7-position in 7-Methyl-5,6,7,8-tetrahydroimidazo1,2-apyridine is particularly noteworthy, as it can influence the compound's solubility, bioavailability, and binding affinity to biological targets. The tetrahydroimidazole moiety enhances the compound's ability to penetrate cell membranes, while the pyridine ring contributes to its stability and metabolic profile.

In the context of contemporary pharmaceutical research, 7-Methyl-5,6,7,8-tetrahydroimidazo1,2-apyridine has been explored for its potential role in modulating signaling pathways associated with various diseases. For instance, preclinical studies have suggested that this compound may interfere with the activity of kinases and other enzymes involved in cancer progression. The imidazole ring is known to exhibit inhibitory effects on several enzymes that are overexpressed in tumor cells. This makes 7-Methyl-5,6,7,8-tetrahydroimidazo1,2-apyridine a valuable scaffold for developing novel anticancer agents.

Moreover, the compound's structural similarity to known bioactive molecules has prompted researchers to investigate its potential in treating inflammatory disorders. Chronic inflammation is a hallmark of many diseases, including autoimmune conditions and metabolic syndromes. By targeting inflammatory pathways such as NF-κB and MAPK cascades, 7-Methyl-5,6,7,8-tetrahydroimidazo1,2-apyridine may offer therapeutic benefits. Initial in vitro studies have demonstrated its ability to reduce pro-inflammatory cytokine production in activated immune cells. This suggests that the compound could be developed into a novel anti-inflammatory drug.

The synthesis of 7-Methyl-5,6,7,8-tetrahydroimidazo1,2-apyridine involves multi-step organic reactions that require precise control over reaction conditions. Advanced synthetic methodologies have been employed to optimize yield and purity. Techniques such as catalytic hydrogenation and palladium-catalyzed cross-coupling reactions are commonly used in its preparation. These methods ensure that the final product meets the stringent standards required for pharmaceutical applications.

One of the key advantages of 7-Methyl-5,6，7，8-tetrahydroimidazo1，2-apyridine is its versatility as a chemical scaffold. By modifying various functional groups within its structure， researchers can generate a library of derivatives with tailored pharmacological properties。 This flexibility allows for rapid screening and optimization of lead compounds for specific therapeutic targets。 The imidazole ring can be further functionalized to enhance binding affinity or alter metabolic stability， while the pyridine moiety provides opportunities for further derivatization。

Recent advances in computational chemistry have also facilitated the study of 7-Methyl-5，6，7，8-tetrahydroimidazo1，2-apyridine's interactions with biological targets。 Molecular docking simulations have been used to predict how this compound binds to enzymes and receptors involved in disease pathways。 These predictions guide experimental efforts by identifying key residues critical for binding affinity。 Additionally， virtual screening techniques have enabled high-throughput identification of potential drug candidates based on structural similarity to known bioactive molecules。

The pharmacokinetic profile of 7-Methyl-5，6，7，8-tetrahydroimidazo1，2-pyridine is another area of active investigation。 Studies have examined its absorption、distribution、metabolism、and excretion (ADME) properties using both in vitro and in vivo models。 These studies are crucial for understanding how the compound behaves within an organism and for predicting its clinical efficacy and safety。 Preliminary data suggest that CAS No 144042 -81 -9 exhibits favorable pharmacokinetic characteristics， including moderate solubility、reasonable bioavailability、and slow metabolism rates。

Future directions for research on CAS No 144042 -81 -9 include exploring its potential in combination therapies。 By pairing this compound with other drugs that target different aspects of disease pathways， researchers may enhance therapeutic outcomes. Additionally， investigating its effects in animal models will provide further insights into its clinical potential。 Preclinical trials are necessary to evaluate its safety profile、optimal dosing regimens、and long-term effects before human testing can begin。

The development of novel pharmaceutical agents relies heavily on interdisciplinary collaboration between chemists、biologists、pharmacologists、and clinicians。 The study of compounds like CAS No 144042 -81 -9 exemplifies this collaborative approach by integrating synthetic chemistry、computational modeling、biological assays、and preclinical testing into a cohesive research framework。 Such efforts are essential for advancing our understanding of disease mechanisms and developing effective treatments。

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)